Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . A SINO BIOPHARMACEUTICAL LIMITED 中國 生物 製藥 有限公司 ( Incorporated in the Cayman Islands with limited liability ) Website : www.sinobiopharm.com ( Stock code : 1177 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE , 2021 FINANCIAL HIGHLIGHTS For the six months end 30 June , 2021 RMB'000 2020 Change RMB'000 % Revenue Gross profit 14,353,781 12,647,775 + 13.5 % 11,600,660 9,855,731 + 17.7 % Profit for the period 9,641,604 2,064,127 + 367.1 % Profit attributable to the owners of the parent 8,480,340 1,240,612 + 583.6 % Profit attributable to the owners of the parent excluding the share of profits / ( losses ) of associates and joint ventures ( net of related tax ) 1,574,765 1,281,800 + 22.9 % Sales of new products ( Note ) 6,300,563 4,405,867 + 43.0 % Share of revenue 43.9 % 34.8 % Sales of oncology medicines 5,025,351 4,017,557 + 25.1 % Share of revenue 35.0 % 31.8 % The Board of the Company has declared the payment of a quarterly dividend of HK2 cents per share for the three months ended 30 June , 2021. Together with the first quarterly dividend of HK2 cents per share paid , the total dividend of first two quarters amounted to HK4 cents per share . Note : Products launched within five years . 1